Additionally, the amino acid valine was inadvertently inserted (*i.e.*, a typographical error) at position 341 of SEQ ID NO:2 in applicants' previous Preliminary Amendments (filed 07 October 1999 and 03 January 2000) made in response to an invitation to correct defects in the originally-filed Sequence Listing for the underlying U. S. parent application (Serial No. 09/234,208). This inadvertent insertion was perpetuated in the present CIP filing.

Accordingly, applicants now delete this valine residue, resulting in a 419 amino acid sequence for SEQ ID NO:2 as it was listed in applicants' original Sequence Listing for the underlying U. S. parent application (Serial No. 09/234,208). Support for this amendment is found in the originally-filed Sequence Listing of the parent, and throughout the current and parent specification and claims, which refer to an amino acid sequence (for SEQ ID NO:2) of up to about 419 amino acids.

The present inventor listing conforms to the true inventors as reflected in our Petition to Correct Inventorship which will be submitted under separate cover.

Applicants assert that the presently submitted Sequence Listing not only conforms with that of the underlying U. S. parent application (Serial No. 09/234,208), but also with the requirements of C.F.R. 1.821-1.825, and brings applicants' current specification into conformity with the presently-submitted Sequence Listing. No new matter has been added.

Applicants, in concert with this Preliminary Amendment, have responded to the above-identified NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES.

Respectfully submitted,

Barry L. Davison

Attorney for Applicants Registration No. 47,309

Davis Wright Tremaine LLP 2600 Century Square 1501 Fourth Avenue Seattle, WA 98101-1688 Tel 206-628-7621 Fax 206-628-7699

15

25

30

SEQUENCE LISTING

GENERAL INFORMATION:

- (i) APPLICANTS: Clinton, Gail M., Adam Evans and William D. Henner
 - (ii) TITLE OF INVENTION: HER-2 BINDING ANTAGONISTS
- 10 (iii) NUMBER OF SEQUENCES: 10
 - (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: DAVIS WRIGHT TREMAINE
 - (B) STREET: 1501 Fourth Avenue, 2600 Century Square
 - (C) CITY: Seattle
 - (D) STATE: Washington
 - (E) COUNTRY: U.S.A.
 - (F) ZIP: 98101
- 20 (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: PC compatible
 - (C) OPERATING SYSTEM: Windows 95
 - (D) SOFTWARE: Word
 - (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER: 09/506,079
 - (B) FILING DATE: 16 February 2000
 - (C) CLASSIFICATION;
 - (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Davison, Barry L.
 - (B) REGISTRATION NUMBER: 47,309
 - (C) REFERENCE/DOCKET NUMBER: 49321-16
 - (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 206 628 7621
 - (B) TELEFAX: 206 628 7699
 - (2) INFORMATION FOR SEQ ID NO:1:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 79
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: unknown

34

35

40

45

	(ii) MOLECULE TYPE: HER-2 ECD antagonist (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:															
5	_				5					10	Ala				15	
	Arg	Xaa	Gln	Pro 20	Xaa	Pro	Ala	His	Pro 25	Val	Leu	Ser	Phe	Le⁄u 20	Arg	Pro
	Ser	Trp	Asp 35	Xaa	Val	Ser	Ala	Phe 40	Tyr	Ser	Leu	Pro	Lev/	Ala	Pro	Leu
10	Ser	Pro 50	Thr	Ser	Val	Xaa	Ile 55	Ser	Pro	Val	Ser	Val	/Gly	Arg	Gly	Xaa
	Asp 65		Asp	Ala	His	Val 70	Ala	Val	Xaa	Leu	Ser	Mrg	Tyr	Glu	Gly	
15																
	(2)	INFO	ORMAT	rion	FOR	SEQ	ID N	JO:2	:							
20		(i)		A) LI	ENGTI	I: 41	CTERI 19 10 ac		cs: /							
_,		(ii)	(C	C) ST O) T(TRANI OPOLO	DEDNE DGY:	ESS: unkr poly	sing nown								
25		(xi)					PTIC			ID NO	0:2:					
25	Met	Glu	Leu	Ala	Ala 5	Leu	Cys	Arg	Trp	Gly 10	Leu	Leu	Leu	Ala	Leu 15	Leu
	Pro	_			_					10						
		Pro	Gly	Ala 20	Ala	Ser	Thr	Gln	Val 25		Thr	Gly	Thr	Asp 30	Cys	Lys
30	Leu		-	20					25	Cys	Thr Leu	_		30	_	
30		Arg	Leu 35	20 Pro	Ala	Ser/	Pro	Glu 40	25 Thr	Cys		Asp	Met 45	30 Leu	Arg	His
	Leu Leu	Arg Tyr 50	Leu 35 Gln	20 Pro Gly	Ala Cys	Ser/	Pro Val 55	Glu 40 Val	25 Thr Gln	Cys His Gly	Leu Asn Gln	Asp Leu 60	Met 45 Glu	30 Leu Leu	Arg Thr	His Tyr Val
30	Leu Leu 65	Arg Tyr 50 Pro	Leu 35 Gln Thr	20 Pro Gly Asn	Ala Cys Ala Leu	Ser Øln Ser 70	Pro Val 55 Leu	Glu 40 Val Ser	25 Thr Gln Phe	Cys His Gly Leu Gln	Leu Asn	Asp Leu 60 Asp	Met 45 Glu Ile	30 Leu Leu Gln	Arg Thr Glu Pro	His Tyr Val 80
	Leu Leu 65 Gln	Arg Tyr 50 Pro	Leu 35 Gln Thr	20 Pro Gly Asn Val	Ala Cys Ala Leu 85	Ser Øln Ser 70 Cys	Pro Val 55 Leu Ala	Glu 40 Val Ser	25 Thr Gln Phe Asn Thr	Cys His Gly Leu Gln 90	Leu Asn Gln 75	Asp Leu 60 Asp	Met 45 Glu Ile Gln	30 Leu Leu Gln Val	Arg Thr Glu Pro 95	His Tyr Val 80 Leu
	Leu Leu 65 Gln	Arg Tyr 50 Pro Gly Arg	Leu 35 Gln Thr Tyr	20 Pro Gly Asn Val Arg	Ala Cys Ala Leu 85 Ile	Ser/ Øln Ser 70 Cys	Pro Val 55 Leu Ala Arg	Glu 40 Val Ser His	25 Thr Gln Phe Asn Thr 105	Cys His Gly Leu Gln 90 Gln	Leu Asn Gln 75 Val	Asp Leu 60 Asp Arg	Met 45 Glu Ile Gln Glu	30 Leu Leu Gln Val Asp 110	Arg Thr Glu Pro 95 Asn	His Tyr Val 80 Leu Tyr
35	Leu 65 Gln Gln Ala	Arg Tyr 50 Pro Gly Arg Leu	Leu 35 Gln Thr Tyr Leu Ala 119	20 Pro Gly Asn Val Avg 100 Val	Ala Cys Ala Leu 85 Ile Leu	Ser/ Gln Ser 70 Cys Val Asp	Pro Val 55 Leu Ala Arg Asn	Glu 40 Val Ser His Gly Gly 120	25 Thr Gln Phe Asn Thr 105 Asp	Cys His Gly Leu Gln 90 Gln Pro	Leu Asn Gln 75 Val Leu	Asp Leu 60 Asp Arg Phe	Met 45 Glu Ile Gln Glu Agn 125	30 Leu Leu Gln Val Asp 110 Thr	Arg Thr Glu Pro 95 Asn Thr	His Tyr Val 80 Leu Tyr
35	Leu 65 Gln Gln Ala Val	Arg Tyr 50 Pro Gly Arg Leu Thr 130	Leu 35 Gln Thr Tyr Leu Ala 115 Gly	20 Pro Gly Asn Val Ayg 100 Val	Ala Cys Ala Leu 85 Ile Leu Ser	Ser/ Øln Ser 70 Cys Val Asp	Pro Val 55 Leu Ala Arg Asn Gly 135	Glu 40 Val Ser His Gly Gly 120 Gly	25 Thr Gln Phe Asn Thr 105 Asp	Cys His Gly Leu Gln 90 Gln Pro Arg	Leu Asn Gln 75 Val Leu Leu	Asp Leu 60 Asp Arg Phe Agn Leu 140	Met 45 Glu Ile Gln Glu Agn 125 Gln	30 Leu Leu Gln Val Asp 110 Thr	Arg Thr Glu Pro 95 Asn Thr	His Tyr Val 80 Leu Tyr Pro

```
Asn Gln Leu Ala Leu Thr Leu Ile Asp Thr Asn Arg Ser Arg Ala Cys
                                                         190
    His Pro Cys Ser Pro Cys Cys Lys Gly Ser Arg Cys Trp Gly Glu ≸er
                                 200
    Ser Glu Asp Cys Gln Ser Leu Thr Arg Thr Val Cys Ala Gly Gly Cys
5
                                                 220
                            215
    Ala Arg Cys Lys Gly Pro Leu Pro Thr Asp Cys Cys His Glu/Gln Cys
                        230
                                             235
    Ala Ala Gly Cys Thr Gly Pro Lys His Ser Asp Cys Leu Ala Cys Leu
10
                    245
                                         250
    His Phe Asn His Ser Gly Ile Cys Glu Leu His Cys Pro/Ala Leu Val
                                     265
    Thr Tyr Asn Thr Asp Thr Phe Glu Ser Cys Pro Asn Pro Glu Gly Arg
            275
                                 280
15
    Tyr Thr Phe Gly Ala Ser Cys Val Thr Ala Cys Prø Tyr Asn Lys Leu
                            295
    Ser Thr Asp Val Gly Ser Cys Thr Leu Val Cys Pro Leu His Asn Gln
                        310
    Glu Val Thr Ala Glu Asp Gly Thr Gln Arg Cys Glu Lys Cys Ser Lys
20
                                         330
                    325
    Pro Cys Ala Arg Gly Xaa His Ser Xaa Xaa Pro Arg Pro Ala Ala Val
                                     345
                                                         350
                340
    Pro Val Pro Xaa Arg Xaa Gln Pro Xaa Fro Ala His Pro Val Leu Ser
                                 360
                                                     365
    Phe Leu Arg Pro Ser Trp Asp Xaa Va/1 Ser Ala Phe Tyr Ser Leu Pro
25
                             375
    Leu Ala Pro Leu Asp Pro Thr Ser/Val Xaa Ile Ser Pro Val Ser Val
                                             395
                                                                  400
                        390
    385
    Gly Arg Gly Xaa Asp Pro Asp Ala His Val Ala Val Xaa Leu Ser Arg
30
                    405
                                         410
    Tyr Glu Gly
```

(2) INFORMATION FOR SEQ/ID NO:3:

35

40

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 19
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single

(D) ŢŐPOLOGY: unknown

- (ii) MOLECULE TYPE: oligonucleotide
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

TGAGCACCÁT GGAGCTGGC 19

45

(2) INFORMATION FOR SEQ ID NO:4:

	(i) SEQUENCE CHARACTERISTICS:
1	(A) LENGTH: 22
	(B) TYPE: nucleic acid
5	(C) STRANDEDNESS: single
	(D) TOPOLOGY: unknown
	(ii) MOLECULE TYPE: oligonucleotide
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:
10	TCCGGCAGAA ATGCCAGGCT CC 22
	(2) INFORMATION FOR SEQ ID NO:5:
	(i) SEQUENCE CHARACTERISTICS:
15	(A) LENGTH: 22
13	(B) TYPE: nucleic acid
	(C) STRANDEDNESS: single
	(D) TOPOLOGY: unknown
	(ii) MOLECULE TYPE: oligonucleotide
20	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:
20	(XI) SEQUENCE DESCRIPTION: SEQ ID NO.3.
	AACACAGCGG TGTGAGAAGT GC 22
	· /
25	(2) INFORMATION FOR SEQ ID NO:6/:
	(i) SEQUENCE CHARACTERISTICS:
	(A) LENGTH: 21
	(B) TYPE: nuclei¢ acid
30	(C) STRANDEDNESS: single
	(D) TOPOLOGY: /unknown
	(ii) MOLECULE TYPE; oligonucleotide
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:
25	171 000001 0 100T011 010 0 01
35	ATACCGGGAC AGGTCAACAG C 21
	(2) INFORMATION FOR SEQ ID NO:7:
	(i) SEQUENCE CHARACTERISTICS:
40	(A) LENGTH: 20
40	(B) TYPE: nucleic acid
	(2) STRANDEDNESS: single
	(b) TOPOLOGY: unknown
	(ii) MOLECULE TYPE: oligonucleotide
45	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:
	Control 2220MI 120M 522 13 MOVV
	TCTGGGTACC CACTCACTGC 20

5	(2)	(ii)	SEQ (A (E (C (D MOL	UENC) LE) TY) ST) TC LECUI	CE CHENGTHE PROPERTY OF THE TYPE TO THE TYPE THE TYPE THE THE THE THE THE THE THE THE THE TH	HARAC H: 22 nucl DEDNE DGY: YPE:	CTERI Peic SS: unkr	acio sino nown	CS: d gle cleot):8:			
	TTCA	CACT	GG C	CACGI	CCAC	GA CO	22					/		
15	(2)	INFO	SEÇ (A	UENC	CE CH ENGTH	IARAC I: 27	CTERI 7	NO:9: ISTIC	CS:		/			
20			O) IOM	S) ST O) TO LECUI	TRANI DPOLO LE TY	DEDNE DGY : YPE :	ESS: unkr olig	sing	gle/ cl/eot):9:			
25	GCAC	GGAT(CC A	\TAG(CAGAC	CT GA	AGGA	3G/27	7 ·					
	(2)	INFO	RMAT	CION	FOR	SEQ	ID/1	, 10:10):					
30°		(i)	(A (E (C	L) LE 3) TY C) ST	ENGTH PE:	i: 2/1 nyc] DEDNI	ío ba Leic ESS:	ISTIC ase p acic doub	pairs 1	3				
35		(ii) (xi)	MOL	ECUI	LE TX	PE:	DNA	ON: S	SEQ 1	D NO	0:10:	:		
		WCC (Xaa]			,									45
40		CGC A	,											90
45		CCC Pro												135

	/																
M	.1	GCC	CCC	CTC	AGC	CCT	ACA	AGT	GTC	CST	ATA	TCC	ССТ	GTC	AGT	E TG	180
MON	yule	Ala	Pro	Leu	Ser		Thr	Ser	Val	Xaa		Ser	Pro	Val	Ser/		
	5					50					55					60	
		GGG	AGG	GGC	CYG	GAC	CCT	GAT	GCT	CAT	GTG	GCT	GTT	SAC	CTG	TCC	225
		Gly	Arg	Gly	Xaa	Asp	Pro	Asp	Ala	His	Val	Ala	Val	X <i>a</i> /a	Leu	Ser	
						65					70		/			75	
	10	CGG	TAT	GAA	GGC	TGA											240
		Arg	Tyr	Glu	Gly												